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ABSTRACT
Background: The key to interpreting the contribution of a disease-associated 
mutation in the development and progression of cancer is an understanding of the 
consequences of that mutation both on the function of the affected protein and on 
the pathways in which that protein is involved. Protein domains encapsulate function 
and position-speciic domain based analysis of mutations have been shown to help 
elucidate their phenotypes.
Results: In this paper we examine the domain biases in oncogenes and tumour 
suppressors, and ind that their domain compositions substantially differ. Using data 
from over 30 different cancers from whole-exome sequencing cancer genomic projects 
we mapped over one million mutations to their respective Pfam domains to identify 
which domains are enriched in any of three different classes of mutation; missense, 
indels or truncations. Next, we identiied the mutational hotspots within domain 
families by mapping small mutations to equivalent positions in multiple sequence 
alignments of protein domains
We ind that gain of function mutations from oncogenes and loss of function 
mutations from tumour suppressors are normally found in different domain families 
and when observed in the same domain families, hotspot mutations are located at 
different positions within the multiple sequence alignment of the domain.
Conclusions: By considering hotspots in tumour suppressors and oncogenes 
independently, we ind that there are different speciic positions within domain 
families that are particularly suited to accommodate either a loss or a gain of function 
mutation. The position is also dependent on the class of mutation.
We ind rare mutations co-located with well-known functional mutation hotspots, 
in members of homologous domain superfamilies, and we detect novel mutation 
hotspots in domain families previously unconnected with cancer. The results of this 
analysis can be accessed through the MOKCa database (http://strubiol.icr.ac.uk/
extra/MOKCa).
INTRODUCTION
All cancers depend on mutations in critical 
genes that confer a selective advantage to the tumour 
cell. Knowledge of these mutations is fundamental 
to understanding the biology of cancer initiation and 
progression, and to the development of targeted therapeutic 
strategies. The genes that harbour the driver mutations that 
contribute to the disease process are traditionally classiied 
as either as ‘tumour suppressors’ or as oncogenes, 
dependent on their role in cancer development.
When mutations (or epigenetic silencing) of the 
protein products of tumour suppressors result in their 
loss of function (LOF), cancer progression occurs. Driver 
alterations in these genes are typically molecularly 
recessive in nature, with both copies of the gene requiring 
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a LOF defect. In oncogenes, an increase in activity, or a 
change of function is required for tumorigenesis. These 
genes tend to exhibit a molecularly dominant mode of 
action, and usually only one faulty copy of the gene is 
required to provide an oncogenic phenotype [1].
When mutations from cohorts of patients are 
sequenced and the alterations mapped to a single 
genome, the mutational spectra in tumour suppressors 
and oncogenes tend to differ. In tumour suppressors small 
mutations are often liberally dispersed along the length 
of the gene. This is because the protein products can be 
disrupted with damaging mutations at a multitude of 
positions [2, 3]. Driver missense mutations within a tumour 
suppressor can result in its loss of function in a variety 
of ways, including loss of stability of the protein or the 
disruption of a crucial ligand/DNA/protein-interaction site. 
Conversely, in oncogenes often only a very few, speciic 
mutations in speciic locations can lead to activation of 
the protein product or a change of protein function. Driver 
missense mutations consequently tend to cluster at distinct 
locations within a protein [4, 5], impacting on functional 
sites such as ligand-binding, protein-protein interactions, 
allosteric regulation and post-translational modiications.
Several groups have used the differences in these 
mutational patterns to automatically distinguish between 
tumour suppressor and oncogenes [6]. For instance, 
Vogelstein’s 20:20 rule [2] can be applied to cohorts of 
tumour samples. Within a cohort: if 20% of all mutations 
observed within a gene are truncations, then the gene is 
likely to be a tumour suppressor. Similarly, if 20% of 
all missense mutations occur at a single position in the 
sequence, the gene is predicted to be an oncogene.
As well as discriminating between tumour 
suppressors and oncogenes, there are several approaches 
to detect which genes are likely to be drivers, irrespective 
of their biological function: Statistical methods have 
been successfully applied to identify recurrently mutated 
genes within large cohorts of sequenced tumours (eg [7, 
8]). However, the data sets are not yet large enough to 
have the statistical power to detect low frequency mutated 
genes that contribute to the disease process.  This poses a 
problem as most somatic mutations in tumours occur in 
genes that are rarely mutated [9, 10].
An alternative approach to identifying drivers 
uses sequence and structural data to predict whether a 
missense mutation, or small insertion/deletion (indel) 
could contribute to disease by impacting on the function 
of the encoded protein [11, 12]. Sequence conservation is 
used to predict which mutations can be tolerated within a 
protein structure, and protein structures have been used 
for estimating how disruptive a missense mutation might 
be [13]. More recently algorithms have been speciically 
developed to distinguish cancer-associated somatic driver 
missense mutations from passenger mutations. These 
include proile-based methods for assessing missense 
mutations (eg FATHHM [14], Mutation assessor [15], 
TransFIC [16]), and machine learning algorithms for 
assessing the pathogenicity of missense mutations (eg Inca 
[17], CHASM [18]) and indels [19].
While most analysis of cancer mutations has been 
gene-centric, considering encoded proteins as a whole, a 
few studies have focused on the individual protein domains 
affected [20–22]. Larger proteins are often comprised of 
sets of recognizable domains that recur in other proteins 
in various combinations [23]. These domains may be 
thought of as units of evolution, creating protein domain 
families, which share a ‘common ancestor’. A domain can 
exist across multiple proteins with conserved function and 
structure, it follows that similarly located mutations across 
different proteins in the same domain should have similar 
effects on the function of that domain. A well-documented 
example of this is the activating V600E mutation in the 
kinase domain of BRAF [24], which is found in thyroid 
cancer and malignant melanoma.  Comparable activating 
mutations occur at the equivalent position in the kinase 
domain of c-KIT (D816V) in gastrointestinal stromal 
tumours (GIST) and acute myeloid leukaemia (AML), and 
in the kinase domain of FLT3 (D835Y) in AML [4, 25]. 
Similarly, KRAS, NRAS, HRAS all have highly recurrent 
activating mutations at position G12 (KRAS) in the Ras 
domain in a large variety of cancers [4, 21].
Proteome-wide analyses have previously been 
performed to identify domains enriched in missense 
mutations [20, 21, 26, 27] and to identify hotspot positions 
in missense mutations [5, 22, 28–30]. In these studies all 
missense mutations were analysed concurrently rather 
than segregated into those that would likely result in a loss 
of function and for those that would result in a gain.
Here we examine the domain biases in oncogenes 
and tumour suppressors, and have also compared them 
with genes not assigned to these roles and ind that 
their domain compositions substantially differ. We have 
mapped over 1 million mutations from whole-exome 
sequencing cancer genomic projects including data from 
over 30 different types of cancer and identiied which 
domains are recurrently mutated in tumour suppressors, 
oncogenes and throughout the genome. We have divided 
the mutations into three different classes; missense, 
truncations or indels. Finally we identiied the mutational 
hotspots within domain families by mapping small 
mutations to equivalent positions in multiple sequence 
alignments of protein domains. Examining the differences 
in the distribution of the positions of domain hotspots, 
between tumour suppressors and oncogenes, has enabled 
us to identify key positions of activating mutations in a 
variety of domain types. This has enabled us to identify 
putative gain of function mutations in proteins previously 
unassociated with cancer that may be actionable with 
current therapies. The results of this analysis can be 
accessed through the MOKCa database (Mutations, 
Oncogenes and Knowledge in Cancer, http://strubiol.icr.
ac.uk/extra/MOKCa). 
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RESULTS AND DISCUSSION
Functional characterisation of tumour 
suppressors and oncogenes
Using the Cancer Gene Census classiication we 
assigned 133 molecularly recessive genes as tumour 
suppressors and 481 molecularly dominant genes as 
oncogenes. Genes that were labelled as both molecularly 
dominant and recessive were included in both data sets.
First we analysed the biological pathways. Pathway 
enrichment analysis showed that tumour suppressors 
and oncogenes usually cluster in different molecular 
pathways. We found 79 pathways enriched with tumour 
suppressors, notably those involved in the cell cycle, 
response to cellular stresses and the DNA damage 
response. The 306 pathways enriched in oncogenes 
include those involved in the regulation of biosynthetic 
process, regulation of transcription and those involved in 
protein amino acid phosphorylation. Only 14 pathways 
were enriched in tumour suppressors and oncogenes. 
These included immune system development, regulation 
of macromolecule metabolic process, and regulation of 
cell proliferation and apoptosis.
Although generally segregating onto different 
pathways, the functions of the large majority of the 
proteins in oncogenes and tumour suppressors were 
somewhat similar (see Supplementary Figure 1), with 
the largest class of proteins being enzymes, (TS: 32% 
OG: 18%), transcription factors (TS: 11%, OG: 21%) 
and nucleic acid binding proteins (TS: 32%, OG: 24%) 
with tumour suppressor comprising of signiicantly 
more enzymes (P = 0.000082) and oncogenes of more 
transcription factors (P = 0.0023).
Domain characterisation of tumour suppressors 
and oncogenes
Next we analysed the domain compositions within 
tumour suppressors and oncogenes. In total 5523 Pfam 
domain families were identiied within the 17537 proteins 
analysed. Tumour suppressor proteins contained 197 
different types of Pfam domains with the most frequently 
observed domains including Helicase_C (7), DEAD (4), 
SET (4), HMG-box (3), F-box-like (3), ARID (3), and 
PHD inger (zf-HC5HC2H, 3) domains and the C-terminal 
domain from DNA mismatch repair proteins (DNA_mis_
repair, 3).  Of the 310 Pfam domain types found in our set 
of oncogenes the most frequently observed were Pkinase_
Tyr (26), Homeobox (16), HLH (14), Ets (9), and SH2 (9) 
domains. 
We only found 44 domain types common to tumour 
suppressor and oncogenes. The majority of these were 
either protein binding modules (Ank, WD40, C2, PHD and 
SET domains) or modules evolved to bind to nucleic acids 
(Homeobox, ARID, zf-C2H2, MH1 domains, see Figure 1). 
Despite a substantial number of catalytic domains occurring 
in in TS and OG, only 5 enzyme types were common to 
both; the serine/threonine (Pkinase) and tyrosine protein 
kinases (Pkinase_Tyr), phosphatidylinositide 3-kinases 
(PI3_PI4_kinase), ubiquitin carboxyl-terminal hydrolase 
(UCH) and the JmjC protein hydroxylase.
Identifying tumour suppressors and oncogenes 
using domain biases
As the domain compositions between these cancer 
genes differed substantially, we decided to investigate 
whether a gene could be classiied as a tumour suppressor 
or an oncogene based on their domain composition 
alone, using a machine learning approach. Our training 
set comprised a list of oncogenes and a list of tumour 
suppressors derived from the Cancer Gene Census (CGC). 
Using a support vector machine classiier and a 10-fold 
cross validation protocol, we achieved a ROC AUC sore 
of 0.72 (see Supplementary Methods) suggesting that the 
classiier has some predictive value. 
We ran the classiier on 37 genes labelled as both 
oncogene and tumour suppressor in the CGC.  We 
found that 17 of the genes were predicted to be tumour 
suppressors with probabilities greater than 0.78, including 
DDB2, TP53 and DAXX. Nine genes were classiied as 
oncogenes with probabilities greater than 0.83, including 
ERBB4, BCL10 and BTK. We could not resolve the 
classiication of 11 genes using this approach (see 
Supplementary Table 1). 
Although this classiication approach may give a 
guide to the gene’s predominant cancer role within the 
cell, there is increasing evidence in the literature that 
depending on cell type and cancer type, many genes can 
function as both a tumour suppressor and as an oncogene 
dependent on the alteration in question.
Mutational characterisation of domains in 
tumour suppressors and oncogenes
To deine the mutational ‘load’ that the different 
domain types are subjected to in cancers, we mapped 
mutations from Cosmic v71 (WGS) whole genome 
sequencing cancer studies onto the Pfam domains 
identiied above. Mutations were grouped into three 
subsets; missense, truncating (nonsense or frameshift), and 
indels (inframe insertion and deletions). In total, 727,525 
missense, 69,414 truncation and 2,958 indel mutations 
from over 30 different types of cancer were mapped to 
Pfam domains within the human genome.
Mutational enrichment in tumour suppressors
The most frequently reported mutational event that 
changes the protein product of tumour suppressors (62%) 
is the missense substitution. However, only 15 domain 
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families were signiicantly enriched in missense mutations 
(see Figure 2A and Supplementary Table 2). The majority 
of these were from single members of a domain family, 
observed within one of the frequently mutated and very 
well studied tumour suppressor genes. These included 
the P53 DNA binding domain (P53) in TP53, the dual 
speciicity phosphatase catalytic domain (DSPc) in PTEN 
and the von Hippel-Lindau disease tumour suppressor 
protein domain (VHL) in VHL. Single amino acids 
substitutions usually destabilise a protein fold [31–32], 
and wild-type TP53, PTEN and VHL are only marginally 
stable at physiological temperatures [33–35], which make 
them particularly sensitive to missense mutations. Only 
WD40 domains had multiple members affected with 
mutations found in DDB2, FBXW7 and TBL1XR1. 
15 domains found in tumour suppressors were 
enriched in truncations, again many being singleton 
domains from the commonly mutated major tumour 
suppressors where a truncation wipes out the complete 
function of the protein. These included domains from the 
protein products of in TP53, VHL, PTEN, RB1 and APC. 
Several domain families including WD40, Bromodomain 
and F-box-like domains displayed truncations in multiple 
members. Only 2 tumour suppressor domains were 
enriched with indels; RhoGAP (PIK3R1) and P53 (TP53) 
each from a single protein (see Figure 2B and 2C and 
Supplementary Tables 3 and 4).
Mutational enrichment in oncogenes
Amino acid changes due to missense mutation 
are also the most frequently reported mutational event 
in oncogenes (85% of all reported mutations). We 
detected 37 domains from our set of oncogenes that 
were signiicantly enriched in missense mutations (see 
Figure 2D and Supplementary Table 5). These include the 
Figure 1: Distribution of molecular function for the 44 domains types found in both oncogenes and tumour suppressors. 
The outer ring shows each Pfam domain type. The inner ring groups the Pfam domains by function.
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classic oncogene tyrosine kinase (Pkinase_Tyr) domain, 
the Ras domain and the isocitrate dehydrogenase domain 
family (Iso_dh), where multiple members of these domain 
families are known to contain highly recurrent gain/change 
of function activating missense mutations. 
Single genes with signiicantly high densities 
of missense mutations included PIK3CA where the 
phosphatidylinositide 3-kinase, the gamma adapter 
protein p101 subunit and the accessory domains are all 
enriched in mutations. Mutations in these domains are 
thought to facilitate allosteric motions that stimulate lipid 
kinase activity required for catalysis on membranes [36]. 
The zinc inger domain (zf-CCCH) in U2AF1 was also 
enriched in mutations. U2AF1, a U2 auxiliary factor 
protein, recognises the AG splice acceptor dinucleotide at 
the 3′ end of introns. Mutations in its zinc inger domains 
have been found to promote enhanced splicing and exon 
skipping in reporter assays in vitro and may have a similar 
effect in vivo [37]. 
Domains that were mutated in more than one gene 
included both furin-like domains which are involved in 
cellular signaling, and immunoglobulin I-set domains 
which are involved in cellular communication. Missense 
mutations in these domains have been shown to disrupt 
protein interaction surfaces, causing disregulation and 
activation of these processes.
Of the 57 domains in oncogenes enriched in 
truncations the majority are derived from a single 
protein (see Figure 2E and Supplementary Table 6). 
They also tend to be present in oncogenes activated 
via a translocation into a fusion protein. It is not clear 
whether these truncations are actually miscalls, and are 
actually translocations that have not been identiied by 
the analysis software or whether these truncations could 
cause activation of the protein by removal of a regulatory 
or binding domain. Alternatively, it may be that when 
not part of a fusion protein the proteins containing 
these domains behave as tumour suppressors rather than 
oncogenes. Examples of domains frequently truncated 
domains include the DNA-binding zinc inger (zf-
H2C2_2) domains in BCL11A, BCL6, PLAG1, ZBTB16, 
ZNF278 and ZNF331. The protein products of these genes 
are thought to repress transcription so disrupting the DNA 
binding domains may result in the expression of different 
subsets of target genes.  Again the sparsity of indel data 
(see Figure 2F and Supplementary Table 7) resulted in 
Figure 2: Domains enriched in mutations in oncogenes and tumour suppressors. The number of domains in the dataset is 
plotted against the estimated mutational enrichment for that domain. Only domains with signiicant mutational enrichment (see methods) 
are shown. Missense, truncation and indel mutational enrichments are calculated independently for tumour suppressors and oncogenes. 
Enrichments in tumour suppressors are coloured in blue, those found in oncogenes in red. (A) Missense mutations in tumour suppressors, 
(B) truncation mutations in tumour suppressors (C) indel mutations in tumour suppressors, (D) missense mutations in oncogenes, (E) 
truncation mutations in oncogenes, (F) indel mutations in oncogenes.
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only 5 domains being identiied as mutationally enriched, 
zf-C2H2, IL6Ra-bind, bZIP_2, PI3K_p85B and Myb_
DNA-bind_6.
Genome-wide mutational enrichment 
We compared the domains observed in tumour 
suppressors and oncogenes with those enriched in 
mutations within the whole genome to see if we could 
identify novel domain families not previously associated 
with annotated cancer driver genes. In total, we detected 
373 domains that were signiicantly enriched in missense 
mutations, of which 340 were not present in our tumour 
suppressor and oncogene datasets (see Supplementary 
Table 8). This suggests that the cancer community may 
be missing mutated genes that contribute to cancer 
progression but may not be the typical cancer genes 
analysed. 
For example, we observed enrichment in mutations 
in the sushi domain also known as known as complement 
control protein (CCP) modules. These are small beta-
sandwiches and function in proteins that are part of the 
innate immune system. Several sushi containing proteins 
have been implicated in the development of tumour cells 
and their loss correlates with poor prognosis [38, 39].
Similarly, in the 225 domains showing enrichment 
in truncations, 196 were not present in the current 
cancer gene set documented in the Cancer Gene Census 
(see Supplementary Table 9). Sushi domains were also 
signiicantly enriched in truncation mutations suggesting 
that the phenotypic role of the missense mutations may be 
loss of function mutations. 
Of the 38 domains signiicantly enriched in 
indels, 31 were not present in our cancer gene lists 
(Supplementary Table 10). 
Detecting domain hotspots
As well as identifying which domain families were 
enriched in mutations, we also wanted to identify the 
key positions within a domain, that when mutated, were 
particularly suited to causing a loss or change in function 
of the protein the domain occurs in. To achieve this we 
created multiple sequence alignments for each domain 
family and counted the mutations at each position in the 
alignment (see Figure 3). A binomial test was applied 
to determine which positions had accrued a signiicant 
number of mutations. Again we analysed tumour 
suppressors and oncogenes, and the different mutation 
types independently (see Table 1). 
Hotspot mutations in tumour suppressors
Within the annotated tumour suppressors we 
identiied 119 missense hotspots within 42 domain 
families, 11 indel hotspots within 7 domain families 
and 73 truncation hotspots in 39 domain families (See 
Supplementary Tables 11–13). The positions of the hotspots 
were dependent on the type of mutation with little overlap 
in the positions of mutations between the different types of 
mutational alterations (see Supplementary Figure 3A). 
The mutational burden of several of the hotspots 
was accrued from a single gene, in particular those found 
in TP53 and VHL. Others were derived from multiple 
tumour suppressor domain family members including 
the Pkinase and WD40 domains. Missense mutations in 
the protein kinase domains from CHEK2 (K373E) and 
MAP2K4 (G252R) have mutations co-located with the 
CDK12 R882L/Q mutations. The CDK12 R882L mutation 
has been shown to impair kinase activity, possibly by 
breaking critical interactions in the active conformation 
of the kinase between phosphorylated threonine 893 
and the activation loop [40], CHEK2 K373E has been 
implicated as a LOF mutation leading to hereditary 
cancer predisposition syndrome. For these two mutations 
there is evidence that they result in a loss of kinase 
activity, suggesting that the mutations occur at a critical 
position in the protein structure when the kinase is in its 
active conformation; the co-located G252R mutation in 
MAP2K4 may also result in a LOF.
Co-located mutations in the WD40 tumour 
suppressors FBXW7 (T385K) and TBL1XR1 (Y395H) 
are also likely to be loss of function. The WD40 domain 
is especially sensitive to position speciic disruption by 
missense mutations because the way in which its fold 
is stabilized. WD40 domains consist of a β-propeller 
structure containing between six to eight propeller 
‘blades’. These blades are each formed by a four-stranded 
antiparallel β-sheet, which are joined by β-hairpins. The 
blades are arranged symmetrically about a central axis, 
and the inside edge of each propellers comprise side 
chains that form a network of hydrogen bonds with each 
other, and internal water molecules that maintain the 
domain’s stability (see Figure 4). Mutating any residue 
that contributes to stabilisation of this central core could 
be catastrophic to the overall fold. In FBXW7, threonine 
385 is located on the irst propeller blade of the WD40, 
forming a hydrogen bond with arginine 674 via a water 
molecule sealing the propeller structure. The replacement 
side chain would be unable to maintain this hydrogen bond 
causing destabilisation of the internal water structure and 
hence the overall fold.
Co-located hotspot mutations were also observed in 
the SNF2 family N-terminal domain (SMARC4;T1747K 
and ATRX;T910M) and the Helicase_C domains 
(ERRC3;R645Q, ATRX;R2153C, SMARCA4; R1192H/
G/C).
The sparsity of both truncation and indel data 
meant that almost all the tumour suppressor hotspots 
were derived from single proteins. Truncation hotspots 
were observed in VHL and P53, in the RhoGAP domain 
in PIK3R1, and the RB_A domain in retinoblastoma 
Oncotarget7www.impactjournals.com/oncotarget
associated protein. Several protein kinase domains had 
truncating mutations at position 14 in the domain multiple 
sequence alignment which would result in complete loss 
of function of the kinase in BUB1B (E813*), MAP3K1 
(Q1247fs*26) and STK11 (D53fs*11). 
TP53 exhibited the most indel hotspots with hotpots 
observed in DNA binding domains (P53) and the P53_
tetramer tetramerisation motif. In several cases multiple 
variants were observed at the same hotspot. This included 
the P53 domain where there was a deletion of residue 113 
F or several residues FLH, and at position 155 there was 
an insertion of DSTPPPGT and a deletion of residues TR 
recorded. 
Hotspots in oncogenes
Within oncogenes we identiied 85 missense hotspot 
in 46 domain families, 10 indel hotspots within 9 domains 
and 42 truncation hotspots in 30 domain families (see 
Supplementary Tables 11–13). Again, the hotspots were 
Figure 3: Domain hotspots. To calculate a domain hotspot all the members of the domain family were aligned using MUSCLE. The 
position of the mutation was mapped to the multiple sequence alignment, and the number of mutations at that position summed. For the 
position to be considered a hotspot, at least two mutations of the same class (missense, truncation or indel) had to be recorded at the same 
position.
Table 1: This table describes the number of recorded and signiicant mutational hotspots identiied 
in each datasets; tumour suppressor, oncogene and whole genome
Gene Type Mutation type #Hotspots #Signiicant
Tumour suppressors
Missense 3720 119
Indels 105 11
Truncations 1206 73
Oncogenes
Missense 7195 85
Indels 63 10
Truncations 1121 42
Whole genome
Missense 65491 954
Indels 1006 113
Truncations 27620 506
Missense, indel and truncation mutations were analysed independently.
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category dependent with only 5 positions of mutations 
in common between the different mutational alterations 
(see Supplementary Figure 3B). Far fewer hotspots 
were observed per domain than in the case for tumour 
suppressors, which supports the conjecture there are only 
certain positions in a domain where a mutation can lead to 
the gain of function or activation that is typically found in 
oncogenes.
We observed the well known, high frequency 
mutations in the Ras (KRAS, HRAS, NRAS), isocitrate 
dehydrogenase (IDH1, IDH2) and tyrosine protein kinase 
domains (BRAF V600E etc). These highly recurrent 
mutations have been extensively analysed and are thought 
to cause a gain/change of function of the protein by 
changing the canonical conformation of the protein.
The small GTPases (K-RAS, N-RAS and H-RAS) 
are molecular switches cycling between the GTP-bound 
active and GDP-bound inactive conformations. They have 
co-located hotspots that are implicated in a large variety of 
cancers. When mutated at position 12, the bulky side chain 
of the mutants are thought to lower the GTPase activity 
through a steric interference of the catalytic process [41]. 
This leads to stabilisation of the active conformation 
leading to constitutive activation of downstream effectors 
such as phosphoinositide 3-kinases and Raf kinases.
IDH1 and IDH2 catalyse the oxidative carboxylation 
of isocitrate to α-ketoglutarate. Mutational hotspots at 
R132H in IDH1, and R140Q and R172K in IDH2 alter 
the progression of this reaction. Recent structural work 
suggests that the R132H IDH1 mutation hampers the 
conformational change from the initial isocitrate binding 
state to the pre-transition state, thus causing an impairment 
of enzyme function [42]. This alters the progression 
of this reaction causing the oncometabolite R(-)-2-
Figure 4: WD40 domain. This illustrates the WD40 domain of FBXW7. Threonine 385 is located on the irst propeller blade of the 
WD40, (shown in blue) forming a hydrogen bond with arginine 674 in the inal propeller blade (shown in red) via a water molecule (shown 
as a green ball) helping to stabilise the propeller structure. Replacing the side chain with arginine would mean this hydrogen bond could not 
be formed destabilisation of the internal water structure of the WD40 and hence the overall fold.
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hydroxyglutarate to be formed. R(-)-2-hydroxyglutarate 
is implicated in genomic hypermethylation, leading to 
histone methylation, genomic instability, and inally 
malignant transformation [43].
Other less will documented co-located missense 
hotspot mutations were found in the guanine nucleotide 
binding protein domains (G_alpha). GNAS R201H 
somatic mutation is an activating mutation resulting 
in constitutively activated G-alpha protein and the 
downstream cAMP cascade, independent of TSH signalling 
[44]. This results in the autonomously functioning thyroid 
nodules. The co-located with activating R183 mutations 
observed in GNA11 and GNAQ in uveal melanoma [56].
In the rhodopsin seven transmembrane helix domain 
family the (7tm_1) the thyrotropin receptor (TSHR) 
A623V activating mutations [45] are co-located with 
R251 mutations from the atypical chemokine receptor 
3 (ACKR3). Other domain families with co-located 
missense mutations include the trypsin, 14-3-3, sema, 
frizzled, yeats and jun domain families.
Few of the truncation hotspots in oncogenes were 
observed in more than one protein, suggesting that 
truncating mutations, if they result in a consequence, may 
be speciic to the context of the domain within the larger 
protein, rather than to the domain itself. 
Although the indel data was sparse there was still some 
evidence that co-located indel hotspot mutations in oncogenes 
are activating. Co-located deletions E746_A750delELREA 
and E746_T751delELREAT both cause activation of EGFR 
[46], and are also co-located deletion in BRAF (M484_
N486delMLN) (see Supplementary Tables 11–13).
Hotspots in tumour suppressors and oncogenes 
occur in different positions in the domains
In total we identiied 341 mutational hotspots within 
66 domains in our cancer gene set. The hotspots in tumour 
suppressors and oncogenes occurred in different domain 
types except in 6 domains ( Pkinase, SET, Pkinase_Tyr, 
Tet_JBP, PI3_PI4_kinase, RhoGAP) and when they were 
observed in the same domain type, they were found with 
in different locations in the domain (see Figure 5A–5C). 
Only in 1 position was a hotspot mutation observed (of 
the same category) in both a tumour suppressors and an 
oncogene (see Figure 5D–5F). This was MSA position 117 
in the tyrosine protein kinase domain (Pkinase_Tyr).
Protein kinases (Pkinase and Pkinase_Tyr) can be 
thought of being in equilibrium between the open and 
closed conformations. Usually, other protein kinases 
phosphorylate the activating residues (S/T/Y) - moving 
the conformational equilibrium towards the open, active 
conformation, whereas protein phosphatases remove the 
phosphate groups shifting the conformational equilibrium 
back to the closed, inactive conformation. These processes 
leads to highly regulated control of the conformation and 
activation of kinase domains. 
Dependant on their location within the kinase 
domain, missense mutations will often be better tolerated 
in one or other conformation of the protein kinase resulting 
in an alteration of the conformational equilibrium and 
constitutive activation (or in some cases deactivation) of 
the protein kinase. This is relected in that the positions of 
the hotspots are generally different in the oncogenes and 
tumour suppressor lavours of this domain. This may not 
be the case in position 117 of the Pkinase_Tyr domain. 
Ten oncogene kinases have a mutation in this position, 
including the documented activating mutations FGFR2 
N549S/K/H, the FGFR1 N546K and EGFR R776H 
mutations. However, the tumour suppressor MAP3K13 
has an A218T mutation of unknown consequence at this 
position, which suggests that it may be possible to have a 
driver mutation that deactivates the protein at this position 
alternatively A218T may be an activating mutation.
Genome wide hotspots
The inal part of our analysis was to assess how 
many of the genome–wide hotspots we could putatively 
assign as activating/gain of function, or as loss of 
function. In total there were 954 missense hotspots in 423 
domain families, 113 indels in 93 domain families and 
506 truncations in 382 domain families of which ~11% 
were co-located with an oncogene or tumour suppressor 
hotspot. 
We were able to identify mutations in genes not 
previously related to cancer that aligned with well-
established caner hotspots. These included 14 tyrosine 
protein kinase domains that had missense mutations co-
located with activating BRAF V600E mutation including 
kinase suppressor of ras 2 (KSR2) p.R724W (117) [47], 
mixed lineage kinase domain like (MLKL) p.R264H 
(117) [48] lemour tyrosine kinase 3 (lmtk3) p.L195F 
(117) [49] and HCK P405S (343)[50]. Mutations at this 
position usually activate the kinase domain, suggesting 
that these proteins may be cancer gain of function 
drivers in rare cases. Similarly, 32 receptors from the 
7tm_1 family that had mutations co-located with the 
A623V activating mutation in the thyrotropin receptor 
(TSHR) [45]. These included four chemokine receptors 
including three c-c chemokine receptors CCR3 (I238V), 
CCR6 (I253M), CCR8 (237T) and the CX3X chemokine 
receptor 1, CX3CR1, (I230N). Chemokines are small 
secreted proteins with an ability to prompt the migration of 
leucocytes. Both cell migration and metastasis show some 
similarities to leucocyte traficking, which have lead to 
suggestions that chemokine receptors expressed on cancer 
cells may play a role in cancer development [51].
Of the remaining 89% of hotspots, 94% are located 
in ~700 domain families not yet associated with well-
documented oncogenes and tumours suppressors. This 
included a signiicant hotspot mutation in the AAA+ 
domain (PF00004), a large diverse protein family 
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belonging to the AAA superfamily of P-loop NTP 
hydrolases, that utilise ATP to create conformational 
changes that are transduced into mechanical forces on 
macromolecule substrates. There is a mutation located 
at position 110 in the MSA of the domain. This includes 
mutations in WRN1P1 a DNA damage sensor (R306Q), 
the 26S protease regulatory subunit 6 (PSMC2) (R258H), 
and in paraplegin (SPG7) R391W. Structural analysis 
by SAAPdat [13] and mCSM [52] on SPG7, the only 
available PDB structure (2QZ4), suggests that the R391W 
mutation would destabilise the structure and disrupt 
protein-protein interactions.
MATERIALS AND METHODS
Mutation mapping 
Protein sequences from COSMIC v71 [57] were 
mapped to UniProt [58] protein sequences using MD5 
hashes and BLAST [59] using the MOKCa update 
protocol. Pfam domain boundaries were assigned to 
each protein and Fasta sequence iles generated for each 
domain.
Somatic mutation data was extracted from the 
“Whole Genome Sequencing” (WGS) version of the 
COSMIC database V71 and processed using the MOKCa 
update protocol. 2,399,998 mutations from 15051 patient 
samples in 30 cancer types were mapped to the UniProt 
protein sequences. In total, 1,077,825 (45%) mutations 
could be mapped to conserved Pfam domains [60].
The mutations were classiied into three subsets. 
Missense mutations, where usually a single base substitution 
changes the protein product by a single amino acid. 
Truncating mutations, which incorporate nonsense mutations 
and frameshift insertions and deletions.  Truncations may 
just disrupt a single domain or result in complete destruction 
of the protein for example by nonsense mediated decay. 
Finally, inframe insertions and deletions (indels) were 
Figure 5: Positional analysis of domain hotspots. Analysis of the overlap in the positions of the signiicant hotspots in oncogenes 
and tumour suppressors compared with those found within the whole genome. (A–C) These venn diagrams illustrate that signiicant 
hotspots can occur in the same domain family in oncogenes (pink), tumour suppressors (blue) and in the whole genome (purple). Each circle 
represents the number of domains that contains a hotspot mutation, intersections illustrate when the same domain is found in more than one 
data set. (A) missense mutations (B) truncation mutations and (C) indels mutations. (D–F) These venn diagrams illustrate that signiicant 
hotspots that occur in the same position in domain families in oncogenes, tumour suppressors and within the whole genome; (D) missense 
mutations, (E) truncations (F) indels mutations.
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grouped together as they are relative infrequent, and both 
have the possibility of causing more severe disruptions to 
the protein product than a missense mutations. In total there 
were 727,525 missense, 69414 truncations and 2,958 indels 
mapped to 17,536 protein domains.
Functional classiication of TS and OG
The panther functional classiication website was used 
to deine the function of the proteins assigned as tumour 
suppressors and oncogenes. The DAVID website [61] was 
used to identify GO term [62] and KEGG [63] pathway 
enrichment for both datasets. For the 44 domains found 
in both tumour suppressors and oncogenes, the molecular 
function for each domain was assigned individually using 
domain information from Interpro website. 
Enriched domains
To ind the domains enriched in mutations in tumour 
suppressors and oncogenes we compared the mutational 
frequency for each domain to the mutational frequency of a 
dataset of 450 “random” domains not related to cancer using 
a chi-square association test [53]. A Bonferroni correction 
was used to identify signiicantly mutated domains. 
Missense, truncations and indels were tested independently.
For the genome-wide study, the mutational burden 
in each single domain type was compared to that in all 
other domain types using a chi-square association test. 
Data was normalized by domain frequency, number of 
samples and domain length.
Hotspot identiication
A suite of Perl programs was used to generate and 
analyse hotspot domain positions. A multiple sequence 
alignment (MSA) was generated for all human domain 
fasta sequences, for each Pfam family using the MUSCLE 
(v3.8.31) alignment program [64]. Each mutation from 
each domain was mapped to a consensus position generated 
from the MSA and a consensus count was generated. 
A binomial test was used to identify which positions 
had a signiicant number of mutations. If each individual 
mutation were to affect a random residue across the 
domain the frequency of mutations at each site would 
follow a binomial distribution. As such our null model 
states that there is an equal probability of a mutation 
occurring at each residue on the given domain.
Where n is the total number of mutations in the 
domain, k is the number of mutations falling at a speciic 
residue and p the probability of any mutation affecting a 
speciic residue we can ind the probability of observing 
k mutations falling at any speciic point in the domain by 
calculating the probability of a minimum of k mutations at 
that point and comparing it to our null model. 
Missense, truncations and indels were tested 
independently and only positions where mutations 
occurred at least two were analysed. The results were 
amended by a Bonferroni correction. The overlap 
of hotspots between different mutational types were 
visualised with jvenn web application [54]
MoKCA database
The MOKCa database (Mutations, Oncogenes 
and Knowledge in Cancer, http://strubiol.icr.ac.uk/extra/
MOKCa) was developed to structurally and functionally 
annotate, and where possible predict, the phenotypic 
consequences of disease-associated mutations in proteins 
implicated in cancer. The initial database focused on 
protein kinases, but has now been extended include all 
the proteins from the human genome that are mutated in 
cancer. 
Populating the database with mutational data 
Somatic mutation data from tumours from the 
COSMIC database (v71) have been mapped to their 
position in UniProt sequences. COSMIC use their own 
reference sequences (Ensembl transcripts), and although 
most COSMIC protein sequences (~17000) match 
perfectly when mapped to UniProt sequences, for the 
remaining ~4000 sequences the relationship is more 
complicated. Each COSMIC sequence was aligned with 
their corresponding UniProt sequence and when the 
sequences are not identical the alignment was stored in 
the database. This allows us to identify the position of 
the mutation with regard to the UniProt sequence, which 
provides the authoritative reference.
Each mutation is described its alteration to the 
protein structure, eg V600E. When this mutation has been 
reported on more one occasion each mutation is stored 
as the same aggregate and an aggregate count given. 
Different genetic changes that result in the same mutation 
are presented together at the protein level. Each disease 
type in which this mutation has been recorded is also 
presented on the protein overview page.
Functional annotation of protein sequences and 
mutations 
Functional annotations for each protein using 
a variety of databases have incorporated this into the 
new MOKCa database. These annotations include the 
identiication and position of Pfam domain assignments 
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within the protein sequence, and the positions of residues 
known or predicted to be affected by post-translational 
modiications including phosphorylation, glycosylation, 
and ubiquitination. Gene Ontology (GO) annotations and 
Prosite patterns [65] have also been obtained for each 
sequence.
Structural mapping of mutations
The amino acid sequence for every Pfam-annotated 
domain for which COSMIC records a cancer-associated 
mutation has been scanned against the Protein Data Bank 
(PDB) [64] using PSI-BLAST, to map the mutation 
onto the protein structure of the affected human protein 
domains where the structure has been experimentally 
determined, or onto the most closely related homologous 
structure where the experimental structure is not known.
To identify which mutations mapped onto residues 
with structural density in the PDB ile, PDB sequence to 
structure alignments from the SIFTS (Structure integration 
with function, taxonomy and sequence) initiative were 
utilized.
Development of web-interface
The new web-interface for MOKCa database can 
accessed at http://strubiol.icr.ac.uk/extra/mokca/ and 
can be searched by gene name or by UniProt accession. 
Users can also “browse the data from the gene data. To 
help identify those proteins we have identiied subsets of 
proteins that are frequently mutated in cancer this includes, 
protein kinases [4], oncogenes and tumour suppressors [1], 
proteins involved in the DNA damage response (DDR) and 
those proteins that are current targets of chemotherapy and 
personalised cancer medicine regimes (drug targets) [55].
CONCLUSIONS
In this study we have used recurrence to identify 
hotspot positions of somatic missense, indel and truncating 
mutations on over 5000 Pfam domain families. We 
analysed the data in tumour suppressors and oncogenes 
separately as we were particularly keen to ind hotspots 
involved in activated proteins, and found that mutational 
hotspots in tumour suppressors and oncogenes usually 
occur in different types of domains, when they do occur in 
the same domain family, they occur at different positions 
in the domain. Our analysis also suggests that there may 
only be a small subset of domain types that can easily be 
activated by single small mutations. 
Missense hotspots were frequently conserved in 
multiple members of Pfam domain families, however 
truncations were conserved far less frequently with many 
truncational hotspots occurring only in individual proteins. 
This may be because truncations often obliterate the 
functioning protein due to processing of the transcript by 
nonsense-mediated decay, so its position within a domain 
is far less crucial than for missense mutations. The large 
number of truncation hotspots observed in the whole 
genome dataset, suggest that there may be a large number 
of tumour suppressors not yet documented. Current 
statistical methods for analysing cohorts of cancer patients 
are designed to identify statistically signiicant mutations 
in single genes. Many of the tumour suppressors are part 
of large protein complexes where failure of any single 
component will result in loss of function of the complex 
as a whole. The mutational burden is thus distributed 
over all components of the complex, with no individual 
subunit being affected at a suficient level to generate a 
statistically detectable signal. 
Using the Cosmic v71 (WGS) we identiied 
several indel mutations conserved in multiple member of 
domain families. As more genome sequencing studies are 
undertaken and the algorithms used to detect indels improve, 
it is likely that more indel hotspots will be identiied. 
We have also used our oncogene and tumour 
suppressor hotspots to identify co-located hotspots in 
167 proteins as yet, not associated with cancer. This 
information enables us to assign putative gain or loss of 
function mutations in these proteins that may contribute 
to cancer progression. Using the biological knowledge 
associated with protein domains, such as structural 
information and evolutionary conservation, enables 
the transfer of knowledge from well studied oncogenes 
to less well studies homologues can lead to testable 
hypotheses of the effect of rare mutations in large cancer 
genomics datasets, and may lead to tractable therapeutic 
intervention points. 
The domain hotspots identiied within this study are 
available though the MOKCa database where mutations 
are annotated by driver types (http://strubiol.icr.ac.uk/
extra/MOKCa).
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